利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3531人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660381, encodeId=d2ae16603818e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：利妥昔单抗可抑制难治性肾病综合征复发, objectType=article, longId=37475, objectId=570a3e475fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=570a3e475fc, replyNumber=0, likeNumber=70, createdTime=2014-10-04, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=570a3e475fc, moduleTitle=Lancet：利妥昔单抗可抑制难治性肾病综合征复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=570a3e475fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660376, encodeId=182c16603e683, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lupus：利妥昔单抗治疗SLE的meta分析, objectType=article, longId=28782, objectId=360f28e8226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=360f28e8226, replyNumber=0, likeNumber=91, createdTime=2014-09-27, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=360f28e8226, moduleTitle=Lupus：利妥昔单抗治疗SLE的meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=360f28e8226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660377, encodeId=b4cc16603e7b9, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet Oncol：Pidilizumab联合利妥昔单抗治疗复发性滤泡状淋巴瘤疗效显著, objectType=article, longId=28792, objectId=8dfe28e926c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dfe28e926c, replyNumber=0, likeNumber=91, createdTime=2014-02-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dfe28e926c, moduleTitle=Lancet Oncol：Pidilizumab联合利妥昔单抗治疗复发性滤泡状淋巴瘤疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dfe28e926c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660382, encodeId=218c166038236, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=姜文奇：利妥昔单抗美罗华临床应用15年的回顾与展望, objectType=article, longId=38314, objectId=a83938314d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a83938314d6, replyNumber=0, likeNumber=83, createdTime=2014-08-08, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a83938314d6, moduleTitle=姜文奇：利妥昔单抗美罗华临床应用15年的回顾与展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a83938314d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660378, encodeId=919b16603e81f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：Idelalisib加利妥昔单抗可显著改善难治性复发CLL生存, objectType=article, longId=30929, objectId=e62130929f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e62130929f4, replyNumber=0, likeNumber=82, createdTime=2014-02-23, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e62130929f4, moduleTitle=NEJM：Idelalisib加利妥昔单抗可显著改善难治性复发CLL生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e62130929f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660379, encodeId=f0d116603e97a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=A&R：利妥昔单抗成功治疗难治性肌炎患者的临床特征, objectType=article, longId=32901, objectId=85d03290135, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85d03290135, replyNumber=0, likeNumber=77, createdTime=2014-07-11, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85d03290135, moduleTitle=A&R：利妥昔单抗成功治疗难治性肌炎患者的临床特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85d03290135)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660371, encodeId=790516603e178, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：利妥昔单抗方案治疗纵隔B细胞淋巴瘤可避免放疗, objectType=article, longId=17564, objectId=f53c1e56400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f53c1e56400, replyNumber=0, likeNumber=86, createdTime=2014-03-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f53c1e56400, moduleTitle=NEJM：利妥昔单抗方案治疗纵隔B细胞淋巴瘤可避免放疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f53c1e56400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660374, encodeId=06ae16603e489, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=AJG：利妥昔单抗可治疗原发性胆汁性肝硬化, objectType=article, longId=21410, objectId=9eb421410bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eb421410bf, replyNumber=0, likeNumber=78, createdTime=2014-04-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eb421410bf, moduleTitle=AJG：利妥昔单抗可治疗原发性胆汁性肝硬化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eb421410bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660373, encodeId=c1bf16603e3e6, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存, objectType=article, longId=21187, objectId=ad0e2118ed1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad0e2118ed1, replyNumber=0, likeNumber=71, createdTime=2013-12-08, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad0e2118ed1, moduleTitle=ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad0e2118ed1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660372, encodeId=a7a416603e2c6, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=ARD：利妥昔单抗治疗可降低RA患者血清致动脉粥样硬化脂蛋白, objectType=article, longId=17721, objectId=c7b11e7214d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7b11e7214d, replyNumber=0, likeNumber=111, createdTime=2013-09-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7b11e7214d, moduleTitle=ARD：利妥昔单抗治疗可降低RA患者血清致动脉粥样硬化脂蛋白, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7b11e7214d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660370, encodeId=ed0e16603e01a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=利妥昔单抗治疗可激发潜伏HBV感染, objectType=article, longId=13705, objectId=228913e0585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=228913e0585, replyNumber=0, likeNumber=88, createdTime=2013-10-29, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228913e0585, moduleTitle=利妥昔单抗治疗可激发潜伏HBV感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=228913e0585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660369, encodeId=d4ed16603699e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=利妥昔单抗使用者应接受HBV筛查仅半数患者被筛查HBV，未及指南建议标准, objectType=article, longId=13523, objectId=ba951352387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba951352387, replyNumber=0, likeNumber=79, createdTime=2013-09-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba951352387, moduleTitle=利妥昔单抗使用者应接受HBV筛查仅半数患者被筛查HBV，未及指南建议标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba951352387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660365, encodeId=9f0b16603656c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=利妥昔单抗对肝炎病毒感染的相关血管炎有效, objectType=article, longId=3768, objectId=3bd03e6852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bd03e6852, replyNumber=0, likeNumber=74, createdTime=2012-05-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bd03e6852, moduleTitle=利妥昔单抗对肝炎病毒感染的相关血管炎有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bd03e6852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660368, encodeId=d7121660368d8, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：R-CHOP联合利妥昔单抗维持治疗对外套细胞淋巴癌老年患者有效, objectType=article, longId=8837, objectId=e072883e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e072883e49, replyNumber=0, likeNumber=79, createdTime=2012-09-24, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e072883e49, moduleTitle=NEJM：R-CHOP联合利妥昔单抗维持治疗对外套细胞淋巴癌老年患者有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e072883e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660366, encodeId=9803166036621, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=利妥昔单抗对HCV相关CV有效, objectType=article, longId=3836, objectId=73f5383688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73f5383688, replyNumber=0, likeNumber=0, createdTime=2012-09-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73f5383688, moduleTitle=利妥昔单抗对HCV相关CV有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73f5383688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660367, encodeId=f816166036e55, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=苯达莫司汀-利妥昔单抗可使惰性淋巴瘤无进展生存期翻番, objectType=article, longId=6773, objectId=4b166e73df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b166e73df, replyNumber=0, likeNumber=80, createdTime=2012-12-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b166e73df, moduleTitle=苯达莫司汀-利妥昔单抗可使惰性淋巴瘤无进展生存期翻番, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b166e73df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660362, encodeId=02b516603627f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤, objectType=article, longId=3000, objectId=35133000eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35133000eb, replyNumber=0, likeNumber=85, createdTime=2012-03-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35133000eb, moduleTitle=利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35133000eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660364, encodeId=b52316603643c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Oncol:CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, objectType=article, longId=3010, objectId=32b2301074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b2301074, replyNumber=0, likeNumber=64, createdTime=2012-05-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b2301074, moduleTitle=Ann Oncol:CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b2301074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660363, encodeId=aaa6166036312, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, objectType=article, longId=3003, objectId=44713003f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44713003f1, replyNumber=0, likeNumber=77, createdTime=2012-02-04, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44713003f1, moduleTitle=CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44713003f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：利妥昔单抗可抑制难治性肾病综合征复发

2014-10-04

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lupus：利妥昔单抗治疗SLE的meta分析

2014-09-27

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet Oncol：Pidilizumab联合利妥昔单抗治疗复发性滤泡状淋巴瘤疗效显著

2014-02-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

姜文奇：利妥昔单抗美罗华临床应用15年的回顾与展望

2014-08-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：Idelalisib加利妥昔单抗可显著改善难治性复发CLL生存

2014-02-23

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

A&R：利妥昔单抗成功治疗难治性肌炎患者的临床特征

2014-07-11

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：利妥昔单抗方案治疗纵隔B细胞淋巴瘤可避免放疗

2014-03-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

AJG：利妥昔单抗可治疗原发性胆汁性肝硬化

2014-04-10

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存

2013-12-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

ARD：利妥昔单抗治疗可降低RA患者血清致动脉粥样硬化脂蛋白

2013-09-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

利妥昔单抗治疗可激发潜伏HBV感染

2013-10-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

利妥昔单抗使用者应接受HBV筛查仅半数患者被筛查HBV，未及指南建议标准

2013-09-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

利妥昔单抗对肝炎病毒感染的相关血管炎有效

2012-05-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：R-CHOP联合利妥昔单抗维持治疗对外套细胞淋巴癌老年患者有效

2012-09-24

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

利妥昔单抗对HCV相关CV有效

2012-09-15

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

苯达莫司汀-利妥昔单抗可使惰性淋巴瘤无进展生存期翻番

2012-12-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤

2012-03-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Oncol:CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率

2012-05-15

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率

2012-02-04

科室
- - 订阅+
  - 更多科室
工具
服务